Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 7/20 | 0.75 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.71 |
| ▸ | MTOR | P42345 | 3/20 | 0.71 |
| ▸ | RAF1 | P04049 | 9/20 | 0.50 |
| ▸ | BRAF | P15056 | 9/20 | 0.50 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15886946 | 0.90 | PIK3R1 (0.81) | PIK3R1PIK3CAMTORRAF1BRAF | |
| SCHEMBL15662085 | 0.86 | PIK3R1 (1.00) | PIK3R1PIK3CAMTORRAF1BRAF | |
| SCHEMBL1310933 | 0.86 | PIK3R1 (0.79) | PIK3R1PIK3CAMTORJAK2 | |
| SCHEMBL1309008 | 0.85 | PIK3R1 (0.57) | PIK3R1PIK3CAMTORRAF1BRAF | |
| SCHEMBL1311445 | 0.83 | PIK3CA (1.00) | PIK3R1PIK3CAMTORWDR5 | |
| SCHEMBL17059110 | 0.83 | PIK3R1 (0.93) | PIK3R1PIK3CAMTORRAF1BRAF | |
| SCHEMBL1310540 | 0.81 | PIK3R1 (0.54) | PIK3R1PIK3CAMTORRAF1BRAF | |
| SCHEMBL18117913 | 0.80 | PIK3CA (0.92) | PIK3R1PIK3CAMTORWDR5 | |
| SCHEMBL1312182 | 0.80 | PIK3R1 (0.52) | PIK3R1PIK3CAMTORRAF1BRAF | |
| SCHEMBL1310735 | 0.80 | PIK3CA (0.57) | PIK3R1PIK3CAMTORRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | PIK3R1 21/4885PIK3CA 2/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.